GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaLundensis AB (XSAT:PHAL BTA) » Definitions » Cyclically Adjusted Price-to-FCF

PharmaLundensis AB (XSAT:PHAL BTA) Cyclically Adjusted Price-to-FCF : (As of Jun. 26, 2025)


View and export this data going back to . Start your Free Trial

What is PharmaLundensis AB Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


PharmaLundensis AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for PharmaLundensis AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaLundensis AB Cyclically Adjusted Price-to-FCF Chart

PharmaLundensis AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PharmaLundensis AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PharmaLundensis AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, PharmaLundensis AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaLundensis AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaLundensis AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PharmaLundensis AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

PharmaLundensis AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

PharmaLundensis AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, PharmaLundensis AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.055/132.8245*132.8245
=-0.055

Current CPI (Mar. 2025) = 132.8245.

PharmaLundensis AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.085 99.995 -0.113
201509 -0.147 100.228 -0.195
201512 0.000 100.276 0.000
201603 -0.029 100.751 -0.038
201606 -0.135 101.019 -0.178
201609 -0.096 101.138 -0.126
201612 0.000 102.022 0.000
201703 -0.076 102.022 -0.099
201706 -0.182 102.752 -0.235
201709 -0.121 103.279 -0.156
201712 0.000 103.793 0.000
201803 -0.080 103.962 -0.102
201806 -0.071 104.875 -0.090
201809 -0.110 105.679 -0.138
201812 0.000 105.912 0.000
201903 -0.066 105.886 -0.083
201906 -0.127 106.742 -0.158
201909 -0.059 107.214 -0.073
201912 0.000 107.766 0.000
202003 -0.082 106.563 -0.102
202006 -0.111 107.498 -0.137
202009 0.017 107.635 0.021
202012 0.000 108.296 0.000
202103 -0.032 108.360 -0.039
202106 -0.064 108.928 -0.078
202109 -0.047 110.338 -0.057
202112 0.000 112.486 0.000
202203 -0.045 114.825 -0.052
202206 -0.012 118.384 -0.013
202209 -0.070 122.296 -0.076
202212 0.000 126.365 0.000
202303 -0.013 127.042 -0.014
202306 -0.077 129.407 -0.079
202309 -0.078 130.224 -0.080
202312 -0.077 131.912 -0.078
202403 -0.054 132.205 -0.054
202406 0.143 132.716 0.143
202409 -0.080 132.304 -0.080
202412 -0.111 132.987 -0.111
202503 -0.055 132.825 -0.055

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PharmaLundensis AB  (XSAT:PHAL BTA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


PharmaLundensis AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of PharmaLundensis AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaLundensis AB Business Description

Traded in Other Exchanges
Address
PharmaLundensis AB, Scheelevagen 2, Lund, SWE, 223 63
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.

PharmaLundensis AB Headlines

No Headlines